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Aim We compared the 2013 American College of Cardiology/American Heart Association (ACC/AHA) and the 2016
European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines on prevention of athero-
sclerotic cardiovascular disease (ASCVD) using different risk prediction models [US Pooled Cohort Equations (US-
PCE for any ASCVD) and European Systematic COronary Risk Evaluation system (European-SCORE for fatal
ASCVD)] and different statin eligibility criteria.
...................................................................................................................................................................................................
Methods and
results
We examined 44 889 individuals aged 40–75 recruited in 2003–09 in the Copenhagen General Population Study,
all free of ASCVD, diabetes, and statin use at baseline. We detected 2217 any ASCVD events and 199 fatal
ASCVD events through 2014. The predicted-to-observed event ratio was 1.2 using US-PCE for any ASCVD and
5.0 using European-SCORE for fatal ASCVD. The US-PCE, but not the European-SCORE, was well-calibrated
around decision thresholds for statin therapy. For a Class I recommendation, 42% of individuals qualified for statins
using the ACC/AHA guidelines vs. 6% with the ESC/EAS guidelines. Using ACC/AHA- vs. ESC/EAS-defined statin
eligibility led to a substantial gain in sensitivity (þ62% for any ASCVD andþ76% for fatal ASCVD) with a smaller
loss in specificity (35% for any ASCVD and 36% for fatal ASCVD). Similar differences between the ACC/AHA
and ESC/EAS guidelines were found for men and women separately, and for Class IIa recommendations. The sensi-
tivity and specificity of a US-PCE risk of 5% were similar to those of a European-SCORE risk of 1.4%, whereas a
US-PCE risk of 7.5% was similar to a European-SCORE risk of 2.4%.
...................................................................................................................................................................................................
Conclusions The ACC/AHA guidelines were superior to the ESC/EAS guidelines for primary prevention of ASCVD, that is, for
accurately assigning statin therapy to those who would benefit.
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Introduction
Atherosclerotic cardiovascular disease (ASCVD) is mainly caused by
modifiable risk factors and is preventable.1 Nevertheless, ASCVD
remains a leading cause of death, disability, and high healthcare costs
worldwide.1,2 The first ASCVD presentation is often sudden and
unexpected death, in which major advances in secondary prevention
are of no help.3 Thus, the only efficient approach to restrict this
undue loss of life, quality of life, and healthcare resources is primary
prevention. For this purpose, public health initiatives are important,4,5
but so is personalized prevention for those at the highest risk.6
The high risk strategy for primary prevention of ASCVD, including
treatment of high blood cholesterol with statins, was revised recently
in both the USA and Europe.7–10 These guidelines, issued by the
American College of Cardiology (ACC) jointly with the American
Heart Association (AHA) and by the European Society of Cardiology
(ESC) jointly with the European Atherosclerosis Society (EAS), are
all endorsing the principle of matching the intensity of preventive
efforts with the absolute ASCVD risk of the individual. However, dif-
ferent risk prediction models are provided to estimate such risk, and
different decision thresholds for, respectively, any ASCVD (ACC/
AHA) and fatal ASCVD (ESC/EAS) are recommended for statin ther-
apy. The risk prediction model recommended in the USA by the
ACC and AHA is the newly introduced Pooled Cohort Equations
(US-PCE) to predict any ASCVD,9,10 and in Europe by the ESC and
EAS is the Systematic COronary Risk Evaluation system (European-
SCORE) to predict fatal ASCVD.7,8
Which risk prediction model to prefer for optimal primary preven-
tion of ASCVD is unknown because the US-PCE and European-
SCORE prediction models have not been compared head-to-head in
the target population. Despite this, a recent current opinion paper
discussed the potential implications of adopting the ACC/AHA guide-
lines in Europe and concluded that the ESC/EAS guidelines using the
European-SCORE model seem to be the most wide ranging, prag-
matic, and appropriate choice for European countries.11 However,
this conclusion was based on the opinion of experts, not a direct
head-to-head comparison of the clinical performance of the guide-
lines using different risk prediction models and Class I and IIa recom-
mendations. This is what we are providing in this study based on a
large, contemporary, population-based European cohort.
Methods
Copenhagen General Population Study
The Copenhagen General Population Study (CGPS) is an ongoing pro-
spective cohort study of the Danish general population.12–16 Enrolment
began in November 2003, and participants are randomly selected
through the Danish Civil Registration system to reflect the Danish popu-
lation aged 20–100 years. All individuals aged 40þ years in Copenhagen
are invited along with a random selection of 25% of individuals aged 20–
39 years. The CGPS covers all regions of Copenhagen including sur-
rounding countryside, and both high- and low-income areas. Information
on baseline examination is provided in the Supplementary material online,
Supplementary material. For this study, we included individuals enrolled
between 2003 and 2009 to secure at least 5 years of follow-up for all indi-
viduals. All individuals were white and of Danish descent. In the main anal-
ysis we excluded individuals with diabetes, pre-existing ASCVD, statin
use or with missing information at baseline examination, resulting in 54
017 individuals available for this study (see Supplementary material online,
Figure S1). Statin users at baseline were excluded because both US-PCE
and European-SCORE were designed to predict the natural history of
ASCVD in the absence of intervention. The study was conducted in
accordance with the Declaration of Helsinki and approved by Herlev and
Gentofte Hospital. Written informed consent was obtained from all
individuals.
Predictors and recommended age range
The predictors used to estimate risk for a first any or fatal ASCVD event
included age, sex, smoking status, total cholesterol, HDL cholesterol, sys-
tolic blood pressure, and treatment for high blood pressure (only
required for risk estimated by US-PCE). US-PCE also includes diabetes,
but for the purpose of this study in which we wanted to compare risk
prediction of US-PCE and European-SCORE in the same population we
excluded individuals with diabetes because European-SCORE is not
applicable in individuals with diabetes.
US Pooled Cohort Equations and European-SCORE vary in the age
ranges to which they apply. European-SCORE is recommended for use in
the 40- to 65-year age range,17,18 and the ESC/EAS guidelines only pro-
vide SCORE-based guidance in this age range.7,8 The electronic version of
SCORE, HeartScore,19 however, allows entry of age up to 100 years, but
the age-related fatal ASCVD risk does not increase beyond age 65. The
age range for US-PCE is 40–79 years,10 but the ACC/AHA guidelines
only provide Class I and IIa guidance based on US-PCE in the 40- to 75-
year age range.9 Thus, in the main analysis we compared the clinical per-
formance of the ACC/AHA and ESC/EAS guidelines in individuals aged
40–75. To comply with real-life clinical use of the ESC/EAS guidelines, the
absolute fatal ASCVD risk for those aged 66–75 was corresponding to
the risk at age 65 when assessing calibration. In the sensitivity analysis, to
follow the ESC/EAS guidelines closely, the study population was limited
to those aged 40–65 (European-SCORE age-range).
Predicted outcomes
With European-SCORE, the predicted outcome is fatal cardiovascular
disease assumed to be caused by atherosclerosis (¼fatal ASCVD).17 The
endpoint defined by US-PCE is first hard ASCVD event, including non-
fatal myocardial infarction, coronary death, and stroke (¼any ASCVD).10
How these outcomes were identified and ascertained for this study is
described in the Supplementary material online, Supplementary material.
Recommendations for statin therapy
The recommended USA and European indications for primary preven-
tion with statins or other lipid-lowering drugs applied in this study are
summarized in Table 1 and specified in the Supplementary material online,
Supplementary material.
Statistical analyses
Calibration of the equations used to estimate predicted risk (US-PCE and
European-SCORE) was assessed by the predicted-to-observed (P/O)
event ratio. As the CGPS has not yet completed 10 years of follow-up for
all individuals, and as all were followed for at least 5 years, we calculated
5-year predicted and observed any ASCVD event rates when assessing
calibration of US-PCE, using the 5-year equations provided by the
REGARDS study.20 Similarly, when assessing calibration of the European-
SCORE equations we calculated the predicted 5-year risk of fatal
ASCVD, and compared predicted with observed 5-year fatal ASCVD
event rates. In the subpopulation recruited in 2004 with complete 10
years of follow-up, we also assessed calibration of US-PCE and
European-SCORE using the 10-year equations. The observed number of
ACC/AHA vs. ESC/EAS guidelines 587
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.any and fatal ASCVD events at 5 and 10 years was adjusted for variable
follow-up time using the Kaplan–Meier estimate, when assessing calibra-
tion. All other analysis was performed using total number of events.
The discriminative power of the US-PCE and European-SCORE equa-
tions was compared with Harrell’s c-statistics, which takes into account
the timing of events.
The proportion of individuals in the CGPS eligible for statin treatment
by the ACC/AHA and ESC/EAS guidelines was calculated using the Class
I and IIa recommendations for primary prevention with statins. These rec-
ommendations are shown in Table 1.
To compare the clinical performance of the guidelines, we calculated
sensitivity, specificity, and the binary net reclassification index (NRI)
across the guideline-defined treatment threshold when comparing the
ACC/AHA and ESC/EAS guidelines. Differences in sensitivity and specific-
ity were statistically compared with the McNemar test. The binary NRI is
the sum of Dsensitivity and Dspecificity and the theoretical range is 2
to 2.21,22
Additional information on statistics is provided in the Supplementary
material online, Supplementary material. Analyses were performed using
Stata version 13.1 SE (StataCorp LP, College Station, TX, USA).
Results
Baseline characteristics and observed events among the 44 889 indi-
viduals aged 40–75 from the CGPS are shown in Table 2; 57% were
women. There were 10 and 14 times more any ASCVD events (used
in US-PCE) than fatal ASCVD events (used in European-SCORE) in
men and women. Supplementary material online, Figure S2 depicts
any and fatal ASCVD event rates stratified by 5-year age groups.
Calibration and discrimination
First, we assessed how accurate the predicted events matched the
observed events (¼calibration). The overall P/O event ratio was 1.2
using US-PCE for any ASCVD compared with 5.0 using European-
SCORE for fatal ASCVD (Figure 1). The US-PCE was well calibrated
around the guideline-defined decision thresholds for statin therapy of
7.5% and 5% (P/O ratio¼ 1.0–1.1), but overestimated risk slightly
when the predicted risk was high (10%, P/O ratio¼ 1.4). In con-
trast, the European-SCORE overestimated risk markedly across all
categories and deciles of predicted risk, with overestimation around
both the high-risk (5%, P/O ratio ¼ 3.6–5.4) and very-high-risk (10%,
P/O ratio¼ 5.4) thresholds for statin therapy (Figure 1). In the 6802
individuals with 10 years of follow-up, we observed similar results
using the 10-year prediction models (see Supplementary material
online, Figure S3).
Next, we assessed the ability of US-PCE and European-SCORE to
discriminate between those who developed events defined by US-
PCE (any ASCVD) and European-SCORE (fatal ASCVD) and those
who did not, after calculating 10-year risk for each individual. For all
comparisons, US-PCE discriminated as well or better than European-
SCORE between cases and non-cases with c-statistics ranging from
0.71 to 0.85 for US-PCE compared with 0.69–0.84 for European-
SCORE (Table 3).
Eligibility for statin therapy
Then, we assessed the proportion of individuals who at baseline
examination would have been eligible for statin therapy according to
the ACC/AHA and ESC/EAS guidelines. We compared correspond-
ing Class I and IIa recommendations as shown in Table 1. For a Class I
recommendation, 42% of individuals qualified for statins using the
....................................................................................................................................................................................................................
Table 1 Guideline recommendations for primary prevention with statins based on total and low-density lipoprotein
cholesterol concentrations and estimated 10-year risk of atherosclerotic cardiovascular disease used in this study
Recommendation ACC/AHA guidelines ESC/EAS guidelines
Class I Lipid-based: Lipid-based:
LDL-C  190 mg/dL (4.9 mmol/L) LDL-C >6 mmol/L (232 mg/dL)
Age  21 years or TC> 8 mmol/L (309 mg/dL)
Class I Risk-based: Risk-based:
LDL-C 70–189 mg/dL (1.8-4.9 mmol/L) LDL-C  4.0 mmol/L (155 mg/dL)
US-PCE  7.5% European-SCORE 5% to< 10% (high risk)
Age 40–75 years Age 40–65 years
LDL-C  2.5 mmol/L (100 mg/dL)
European-SCORE  10% (very high risk)
Age 40–65 years
Class IIa Risk-based: Risk-based:
LDL-C 70–189 mg/dL (1.8–4.9 mmol/L) LDL-C < 4.0 mmol/L (155 mg/dL)
US-PCE 5% to< 7.5% European-SCORE 5% to< 10% (high risk)
Age 40–75 years Age 40–65 years
LDL-C <2.5 mmol/L (100 mg/dL)
European-SCORE  10% (very high risk)
Age 40–65 years
TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; PCE, pooled cohort equations; SCORE, Systematic COronary Risk Evaluation.
588 M.B. Mortensen et al.
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ACC/AHA guidelines vs. 6% with the ESC/EAS guidelines (Figure 2).
Baseline characteristics of these individuals are shown in the
Supplementary material online, Table S1. All who qualified for statin
therapy by the ESC/EAS guidelines also did so with the ACC/AHA
guidelines; in consequence, 36% of all individuals in the CGPS were
furthermore eligible for statin therapy based on Class I recommenda-
tions with the ACC/AHA guidelines, but not with the ESC/EAS
guidelines.
A similar difference between ACC/AHA and ESC/EAS guidelines
was found for men and women separately, and for Class IIa recom-
mendations (Figure 1).
Sensitivity, specificity, and net
reclassification
To compare the ability of ACC/AHA and ESC/EAS guidelines to allo-
cate statin therapy to individuals who later developed any or fatal
ASCVD events, we calculated sensitivity, specificity, and binary NRI
based on Class I recommendations for statin therapy (Table 3 and see
Supplementary material online, Table S2). The ACC/AHA compared
with ESC/EAS guidelines increased the eligibility for statin therapy
both among those who developed any ASCVD (increase in sensitivity
from 10% to 72%) and those who did not develop any ASCVD
(decrease in specificity from 95% to 60%), together yielding a positive
NRI of 0.27. Likewise, the ACC/AHA compared with ESC/EAS guide-
lines increased the eligibility for statin therapy among those who
developed fatal ASCVD (increase in sensitivity from 11% to 87%) and
those who did not develop fatal ASCVD (decrease in specificity from
94% to 59%), yielding a positive NRI of 0.40. Similar results were
seen for men and women separately.
Using the Class IIa recommendations for ACC/AHA compared
with ESC/EAS guidelines, we also observed a large gain in sensitivity
and a positive NRI for both any and fatal ASCVD (see Supplementary
material online, Table S3).
Thresholds of European-SCORE
corresponding to decision thresholds of
US-PCE
Predicted 10-year risk calculated by US-PCE and European-SCORE
correlated strongly (spearman 0.95, P< 0.0001) and linearly
(Figure 3). The sensitivity and specificity of a US-PCE risk of 5% were
similar to those of a European-SCORE risk of 1.4%, while a US-PCE
risk of 7.5% was similar to a European-SCORE risk of 2.4% (Table 4).
Sensitivity analysis
In sensitivity analysis we limited the study population to individuals
aged 40–65 to fully comply with the European-SCORE age-range,
and re-assessed risk prediction and clinical performance of ACC/
AHA and ESC/EAS guidelines. In this age group consisting of 36 482
individuals (see Supplementary material online, Table S4), the US-
PCE likewise were better calibrated than the European-SCORE (P/O
ratio of 1.1 vs. 5.2; see Supplementary material online, Figure S4).
Similar results were observed using the 10-year prediction models
among the 5595 individuals with 10 years of follow-up (see
Supplementary material online, Figure S3). For a Class I recommenda-
tion, 30% of individuals qualified for statins using the ACC/AHA
guidelines vs. 6% with the ESC/EAS guidelines (see Supplementary
material online, Figure S5). The ACC/AHA guidelines increased the
sensitivity for both any and fatal ASCVD events considerably, accom-
panied by smaller decreases in specificity (see Supplementary mate
rial online, Table S5). Thus, for individuals aged 40–65 the ACC/AHA
compared with ESC/EAS guidelines yielded positive NRI of 0.16 for
any ASCVD and of 0.23 for fatal ASCVD. Similar results were
observed in men and women separately, and for Class IIa recommen-
dations (see Supplementary material online, Figure S5 and Table S6).
In a second sensitivity analysis, we included diabetic patients (free of
ASCVD at baseline) resulting in a study population of 46 656 individu-
als [1767(4%) with diabetes]. For a Class I recommendation, 43%
qualified for statins using the ACC/AHA guidelines vs. 9% with the
ESC/EAS guidelines yielding similar clinical performance as in the
main analysis (see Supplementary material online, Table S7). Finally,
...................................................................................................................
....................................................................................................................................................................................................................
Table 2 Baseline characteristics and observed events in individuals in the Copenhagen General Population Study
Age 40–75 years
Characteristics All Men Women
Individuals, n 44 889 19 383 25 506
Age, years 56(48–64) 56(48–64) 56(48–64)
Systolic blood pressure, mmHg 138(125–152) 140(130–155) 135(122–150)
Total cholesterol, mmol/L 5.7(5.1–6.5) 5.7(5.1–6.4) 5.8(5.1–6.5)
High-density lipoprotein cholesterol, mmol/L 1.6(1.3–2.0) 1.4(1.1–1.7) 1.8(1.4–2.1)
Low-density lipoprotein cholesterol, mmol/L 3.3(2.8–4.0) 3.4(2.8–4.0) 3.3(2.7–3.9)
Current smokers, % 22 23 21
US-PCE 10-year any ASCVD risk, % 5.3(1.9–12.3) 9.4(4.2–17.5) 3.1(1.1–7.7)
European-SCORE 10-year fatal ASCVD risk, % 1.6(0.5–4.2) 2.7(1.0–6.0) 0.9(0.2–2.9)
US-PCE-defined any ASCVD events, n 2217 1205 1012
European-SCORE-defined fatal ASCVD events, n 199 126 73
Continuous values are shown as median (interquartile range).
PCE, pooled cohort equations; SCORE, Systematic COronary Risk Evaluation; ASCVD, atherosclerotic cardiovascular disease.
ACC/AHA vs. ESC/EAS guidelines 589
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including statin users (7% of the population) at baseline examination
did not explain the observed mismatch between the predicted and
observed event rates (see Supplementary material online, Figure S6),
and did not change the clinical performance of guidelines (see
Supplementary material online, Table S8).
Discussion
In this large, contemporary, population-based European cohort, the
US-PCE recommended by the ACC/AHA guidelines was better cali-
brated around decision thresholds for statin therapy than the
European-SCORE model recommended by the ESC/EAS guidelines.
Further, the ACC/AHA guidelines were superior to the ESC/EAS
guidelines for primary prevention of ASCVD, that is, for assigning sta-
tin therapy to those who would benefit the most. Thus, based on the
CGPS, these results suggest that the US guidelines have favourable
effects on ASCVD prevention compared with the European
guidelines.
The European perspective
In individuals aged 40–75, recruited from the general population
and free of ASCVD, diabetes and statin use at baseline,<10%
qualified for a Class I or IIa recommendation for statin therapy by
Figure 1 Calibration comparing observed and predicted events in 40- to 75-year-old individuals in the Copenhagen General Population Study. US
PCE performed well below 10% any atherosclerotic cardiovascular disease 10-year risk, with good calibration around the guideline-defined decision
thresholds of 5% and 7.5% for statin therapy (left panel). In contrast, European SCORE overestimated risk across all deciles and categories of fatal
atherosclerotic cardiovascular disease 10-year predicted risk, with substantial overestimation around both the high-risk (5%) and very-high-risk
(10%) thresholds for statin therapy (right panel). Observed events were Kaplan–Meier adjusted. Error bars indicate 95% confidence interval. PCE,
pooled cohort equations; SCORE, Systematic COronary Risk Evaluation.
590 M.B. Mortensen et al.
Downloaded from https://academic.oup.com/eurheartj/article-abstract/38/8/586/2661782
by guest
on 12 February 2018
....................................................................................................................................................................................................................
Table 3 Sensitivity, specificity, and net reclassification based on Class I recommendations for statin eligibility among
individuals aged 40–75 years in the Copenhagen General Population Study
Model comparison Sensitivity
(%)
Specificity
(%)
DSensitivity
(%)
DSpecificity (%) NRI c-Statisticsa P/O
All
Any ASCVD
ESC/EAS 10 95 Ref Ref Ref 0.70
ACC/AHA 72 60 62 (P < 0.0001) 35 (P < 0.0001) 0.27 (P < 0.0001) 0.72 (P < 0.0001) 1.2
Fatal ASCVD
ESC/EAS 11 94 Ref Ref Ref 0.80 5.0
ACC/AHA 87 59 76 (P < 0.0001) 36 (P < 0.0001) 0.40 (P < 0.0001) 0.82 (P ¼ 0.007)
Men
Any ASCVD
ESC/EAS 14 92 Ref Ref Ref 0.69
ACC/AHA 83 43 70 (P < 0.0001) 49 (P < 0.0001) 0.21 (P < 0.0001) 0.71 (P < 0.0001) 1.4
Fatal ASCVD
ESC/EAS 13 92 Ref Ref Ref 0.75 5.1
ACC/AHA 89 41 75 (P < 0.0001) 50 (P < 0.0001) 0.26 (P ¼ 0.001) 0.77 (P ¼ 0.01)
Women
Any ASCVD
ESC/EAS 6 97 Ref Ref Ref 0.70
ACC/AHA 58 73 52 (P < 0.0001) 24 (P < 0.0001) 0.28 (P < 0.0001) 0.71 (P < 0.0001) 0.9
Fatal ASCVD
ESC/EAS 7 97 Ref Ref Ref 0.84 4.0
ACC/AHA 84 72 77 (P < 0.0001) 25 (P < 0.0001) 0.52 (P ¼ 0.0001) 0.85 (P ¼ 0.18)
ac-Statistics for discrimination between events and non-events using US-PCE and European-SCORE.
NRI, net reclassification index; ESC/EAS, European Society of Cardiology/European Atherosclerosis Society; ACC/AHA, American College of Cardiology/American Heart
Association; ASCVD, atherosclerotic cardiovascular disease; P/O, predicted/observed events using European-SCORE and US-PCE.
Figure 2 Eligibility for statin therapy using ACC/AHA and ESC/EAS guidelines in individuals aged 40–75 years in the Copenhagen General
Population Study. Proportion of individuals who qualified for primary prevention with statins based on Class I and IIa recommendations as shown in
Table 1. A larger proportion of individuals qualified for statins with the ACC/AHA guidelines compared with the ESC/EAS guidelines. For conversion
of cholesterol values in mmol/L to mg/dL, multiply by 38.6. ACC/AHA, American College of Cardiology/American Heart Association; ESC/EAS,
European Society of Cardiology/European Atherosclerosis Society; PCE, pooled cohort equations; SCORE, Systematic COronary Risk Evaluation;
LDL-C , Low-density lipoprotein cholesterol; TC , Total cholesterol.
ACC/AHA vs. ESC/EAS guidelines 591
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ESC/EAS guidelines. Because the recommended ‘low-risk’ SCORE
equations overestimated fatal ASCVD risk substantially in this
cohort, even fewer people would have qualified for statin therapy
if well-calibrated equations had been used as recommended.15
Equally troublesome, in people aged 40–75 <15% of those who
later developed a first any or fatal ASCVD event qualified at base-
line for a Class I recommendation for primary prevention with sta-
tin by ESC/EAS guidelines.
European-SCORE overestimated risk substantially in our study,
confirming results obtained recently in another ‘low-risk’ European
cohort, the Rotterdam Study.23 However, we could not confirm
the observed high eligibility for statin treatment by the ESC/
EAS guidelines, most likely because the applicable age range for
European-SCORE was violated in the Rotterdam Study of elderly
people (mean age 66 years), and because the weak Class IIb recom-
mendation for statin therapy in elderly subjects7 was not complied
Figure 3 Correlation between European SCORE fatal atherosclerotic cardiovascular disease 10-year risk and US PCE any atherosclerotic cardio-
vascular disease 10-year risk. Risk estimated by European SCORE and US PCE correlated strongly in the decision interval of interest in both men (A)
and women (B). Analyses were by linear regression. The fitted regression lines include 95% confidence bands (too narrow to be seen). ASCVD, athe-
rosclerotic cardiovascular disease; PCE, pooled cohort equations; SCORE, Systematic COronary Risk Evaluation.
.......................................................... ..........................................................
...................................................................
....................................................................................................................................................................................................................
Table 4 Thresholds of European Systematic COronary Risk Evaluation corresponding to decision thresholds of US
Pooled Cohort Equations and vice versa
Any ASCVD Fatal ASCVD
Cut-point (10-year risk) Sensitivity (%)
PCE/SCORE
Specificity (%)
PCE/SCORE
Sensitivity (%)
PCE/SCORE
Specificity (%)
PCE/SCORE
US-PCE (%) European-SCORE (%)
All
14.6 5.0 47/47 74/75 68/67 79/80
10.0 3.4 62/62 70/71 80/80 69/70
7.5 2.4 71/71 62/62 88/86 61/61
5.0 1.4 81/81 50/49 94/94 48/49
Men
15.7 5.0 58/58 71/72 74/71 70/71
10.0 3.0 77/77 54/55 86/84 53/54
7.5 2.1 84/84 44/45 92/90 42/43
5.0 1.3 92/92 31/32 96/97 30/31
Women
13.0 5.0 34/34 87/88 59/54 87/87
10.0 3.4 45/45 83/81 71/75 83/82
7.5 2.7 55/55 76/75 82/81 74/74
5.0 1.6 68/67 64/64 89/89 63/62
SCORE , Systematic COronary Risk Evaluation; PCE , pooled cohort equations.
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with in the Rotterdam Study. In principle, beyond the age range
of 40–65 years for European-SCORE, the ESC/EAS guidelines only
provide Class I recommendations for statin therapy to patients
with well-defined medical conditions known to be associated with
high- or very-high risk, such as established ASCVD (secondary
prevention), diabetes, chronic kidney disease and familial
hypercholesterolaemia.7,8
The US perspective
When treatment decisions are based on absolute risk for developing
any or fatal ASCVD, accurate estimation of absolute risk is essential
to treat people as intended by the guidelines. Since its introduction
with the 2013 ACC/AHA guidelines, the accuracy (calibration) of the
US PCE calculator24 has been questioned, being accused of overesti-
mating risk.23,25,26 Others, however, have found PCE to be well cali-
brated.11,20 In our contemporary European cohort of whites, US-
PCE was much better calibrated than the European-SCORE model.
Most importantly, and in contrast to European-SCORE, US-PCE was
reasonable well calibrated around the guideline-defined decision
thresholds for statin therapy and thus performed as intended clini-
cally. In our study, the PCE-based ACC/AHA recommendations
resulted in 5–6 times more individuals from the general population
being eligible for statin therapy compared with the SCORE-based
ESC/EAS recommendations. It should be noted that the ACC/AHA
guidelines recommend a clinician–patient discussion to consider
potential benefits and harms of statin therapy, which might lead to
decisions other than those indicated by the Class I and IIa recommen-
dations, including withholding statins in individuals with favourable
risk factors.
Decision thresholds: to treat or not to
treat
Net reclassification index was introduced to evaluate the incremental
value of adding predictors and new biomarkers to established risk
prediction models,27 such as adding HDL-C to SCORE.28 However,
NRI may also be used to compare the clinical performance of differ-
ent risk prediction models,29 as done in this study. Using a clinically
meaningful reclassification approach reflecting the decision ‘to treat
or not to treat’ with statins, the binary NRI was positive and high for
both any and fatal ASCVD when we used the US-PCE-based ACC/
AHA guidelines rather than the European-SCORE-based ESC/EAS
guidelines. Interestingly, although US-PCE discriminated better than
European-SCORE between cases and non-cases the main reason for
the positive NRI was the higher sensitivity of the decision thresholds
defined by ACC/AHA compared with those defined by ESC/EAS.
Consistently, we found that the sensitivity and specificity of a US-PCE
risk of 7.5% were similar to a European-SCORE risk of 2.4%, that is,
well below the currently used 5% high-risk threshold. Interestingly,
we have recently demonstrated that a substantial gain in sensitivity
with a smaller loss in specificity is obtainable by lowering the SCORE-
based decision thresholds.15,30 In support of this, risk–benefit9 and
cost-effectiveness analyses31 indicate that an ideal risk threshold for
primary prevention with statins is around 7.5% 10-year risk for any
ASCVD estimated with well-calibrated US-PCE. Recently, it was sug-
gested that an even lower threshold might also be cost-effective.32
Strength and limitations
A potential limitation of our study is that we only studied white
Europeans, and extrapolation of our results to non-white populations
should be done cautiously. Also, as mean follow-up in the CGPS was
<10 years, we assessed calibration of US-PCE and European-SCORE
using 5-year models, assuming that the correlation of 5- to 10-year
ASCVD events in the CGPS is similar to that observed in the US-PCE
and European-SCORE cohorts. However, in the subpopulation of
individuals with 10 years of follow-up we observed similar calibration
results using 10-year models. Finally, we were not able to adjust for
prescription of preventive medication during follow-up, which might
have contributed to some of the mismatch between predicted and
observed event rates especially among those at higher risk.
A major strength of our study is that the results originate from a
contemporary, population-based, and large cohort with not a single
person lost to follow-up. Any and fatal ASCVD events were appro-
priately identified, which is essential for the assessment of calibration,
and the results are most likely generalizable to most other non-
Eastern European countries, the USA and similar countries. Finally,
our results were robust to several sensitivity analyses.
Conclusion
In this contemporary European cohort with no losses to follow-up,
the ACC/AHA US-PCE model was better calibrated than the ESC/
EAS European-SCORE model. Compared with the ESC/EAS guide-
lines, the ACC/AHA guidelines were superior for primary prevention
of ASCVD, that is, for assigning statin therapy to those who would
benefit the most. Our results thus suggest that the US guidelines have
favourable effects on ASCVD prevention compared with the
European guidelines.
Supplementary material
Supplementary material is available at European Heart Journal online.
Acknowledgement
We thank staff and participants of the Copenhagen General
Population Study for their contributions.
Funding
Herlev and Gentofte Hospital, Copenhagen University Hospital, the
Copenhagen County Foundation, and Aarhus University, all from
Denmark. These are all publicly funded, and neither have any influence
on the research conducted.
Conflict of interest: none declared.
References
1. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med
2013;369:448–457.
2. Laslett LJ, Alagona P Jr, Clark BA III, Drozda JP Jr, Saldivar F, Wilson SR, Poe C,
Hart M. The worldwide environment of cardiovascular disease: prevalence, diag-
nosis, therapy, and policy issues: a report from the American College of
Cardiology. J Am Coll Cardiol 2012;60:S1–S49.
3. Dudas K, Lappas G, Stewart S, Rosengren A. Trends in out-of-hospital deaths
due to coronary heart disease in Sweden (1991 to 2006). Circulation
2011;123:46–52.
ACC/AHA vs. ESC/EAS guidelines 593
Downloaded from https://academic.oup.com/eurheartj/article-abstract/38/8/586/2661782
by guest
on 12 February 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..4. Capewell S, O’Flaherty M. Rapid mortality falls after risk-factor changes in popu-
lations. Lancet 2011;378:752–753.
5. Jørgensen T, Capewell S, Prescott E, Allender S, Sans S, Zdrojewski T, De
Bacquer D, de Sutter J, Franco OH, Løgstrup S, Volpe M, Malyutina S, Marques-
Vidal P, Reiner Z, Tell GS, Verschuren WM, Vanuzzo D, PEP Section of EACPR.
Population-level changes to promote cardiovascular health. Eur J Prev Cardiol
2013;20:409–421.
6. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status,
and future directions. Circulation 2010;121:1768–1777.
7. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O,
Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R,
Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC/EAS Guidelines for
the management of dyslipidaemias: The Task Force for the management of dysli-
pidaemias of the European Society of Cardiology (ESC) and the European
Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769–1818.
8. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney
MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, L½chen M-
L, Lo¨llgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N,
Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Authors/
Task Force Members. 2016 European Guidelines on cardiovascular disease pre-
vention in clinical practice: The Sixth Joint Task Force of the European Society of
Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical
Practice (constituted by representatives of 10 societies and by invited experts):
Developed with the special contribution of the European Association for
Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J
2016;37:2315–2381.
9. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH,
Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS,
Shero ST, Smith SC, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the
treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in
adults. Circulation 2014;129:S1–S45.
10. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R,
Greenland P, Lackland DT, Levy D, O’Donnell CJ, Robinson JG, Schwartz JS,
Shero ST, Smith SC, Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA guideline
on the assessment of cardiovascular risk. Circulation 2014;129:S49–S73.
11. Ray KK, Kastelein JJP, Boekholdt SM, Nicholls SJ, Khaw K-T, Ballantyne CM,
Catapano AL, Reiner Z, Lu¨scher TF. The ACC/AHA 2013 guideline on the treat-
ment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk
in adults: the good the bad and the uncertain: a comparison with ESC/EAS guide-
lines for the management of dyslipidaemias 2011. Eur Heart J 2014;35:960–968.
12. Thomsen M, Nordestgaard BG. Myocardial infarction and ischemic heart disease
in overweight and obesity with and without metabolic syndrome. JAMA Intern
Med 2014;174:15–22.
13. Nordestgaard BG, Palmer TM, Benn M, Zacho J, Tybjaerg-Hansen A, Davey
Smith G, Timpson NJ. The effect of elevated body mass index on ischemic heart
disease risk: causal estimates from a Mendelian randomisation approach. PLoS
Med 2012;9:e1001212.
14. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-
function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med
2014;371:32–41.
15. Mortensen MB, Afzal S, Nordestgaard BG, Falk E. The high-density lipoprotein-
adjusted SCORE model worsens SCORE-based risk classification in a contempo-
rary population of 30 824 Europeans: the Copenhagen General Population
Study. Eur Heart J 2015;36:2446–2453.
16. Mortensen MB, Afzal S, Nordestgaard BG, Falk E. Primary prevention with sta-
tins: ACC/AHA risk-based approach versus trial-based approaches to guide sta-
tin therapy. J Am Coll Cardiol 2015;66:2699–2709.
17. Conroy RM, Pyo¨r€al€a K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De
Bacquer D, Ducimetie`re P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen
T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham
IM. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the
SCORE project. Eur Heart J 2003;24:987–1003.
18. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for
the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol
2009;54:1209–1227.
19. ESC HeartScore risk calculator. http://www.heartscore.org (14 September 2016,
date last accessed)..
20. Muntner P, Colantonio LD, Cushman M, Goff DC, Howard G, Howard VJ, Kissela
B, Levitan EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardi-
ovascular disease pooled cohort risk equations. JAMA 2014;311:1406–1415.
21. Leening MJ, Vedder MM, Witteman JC, Pencina MJ, Steyerberg EW. Net reclassi-
fication improvement: computation, interpretation, and controversies: a litera-
ture review and clinician’s guide. Ann Intern Med 2014;160:122–131.
22. Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS. Net reclassifica-
tion indices for evaluating risk prediction instruments: a critical review.
Epidemiology 2014;25:114–121.
23. Kavousi M, Leening MJG, Nanchen D, Greenland P, Graham IM, Steyerberg EW,
Ikram MA, Stricker BH, Hofman A, Franco OH. Comparison of application of
the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European
Society of Cardiology guidelines for cardiovascular disease prevention in a
European cohort. JAMA 2014;311:1416–1423.
24. ACC/AHA atherosclerotic cardiovascular disease risk calculator. http://tools.acc.
org/ASCVD-Risk-Estimator/ (14 September 2016, date last accessed).
25. Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the
roles of statins, revascularizations, and underascertainment in the Women’s
Health Study. JAMA Intern Med 2014;174:1964–1971.
26. Nissen SE. Prevention guidelines: bad process, bad outcome. JAMA Intern Med
2014;174:1972–1973.
27. Pencina MJ, D’Agostino RB, Pencina KM, Janssens AC, Greenland P. Interpreting
incremental value of markers added to risk prediction models. Am J Epidemiol
2012;176:473–481.
28. Cooney MT, Dudina A, De Bacquer D, Fitzgerald A, Conroy R, Sans S, Menotti
A, De Backer G, Jousilahti P, Keil U, Thomsen T, Whincup P Graham I; SCORE
Investigators. How much does HDL cholesterol add to risk estimation? A report
from the SCORE Investigators. Eur J Cardiovasc Prev Rehabil 2009;16:304–314.
29. Leening MJ, Steyerberg EW, Van Calster B, D’Agostino RB Sr, Pencina MJ. Net
reclassification improvement and integrated discrimination improvement require
calibrated models: relevance from a marker and model perspective. Stat Med
2014;33:3415–3418.
30. Murphy TP, Dhangana R, Pencina MJ, Zafar AM, D’Agostino RB. Performance of
current guidelines for coronary heart disease prevention: optimal use of the
Framingham-based risk assessment. Atherosclerosis 2011;216:452–457.
31. Dea~no RC, Pandya A, Jones EC, Borden WB. A look at statin cost-effectiveness
in view of the 2013 ACC/AHA cholesterol management guidelines. Curr
Atheroscler Rep 2014;16:438.
32. Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-
year risk thresholds for initiation of statin therapy for primary prevention of car-
diovascular disease. JAMA 2015;314:142–150.
594 M.B. Mortensen et al.
Downloaded from https://academic.oup.com/eurheartj/article-abstract/38/8/586/2661782
by guest
on 12 February 2018
